CompletedNot Applicable

Electroconvulsive Therapy Versus Intravenous Ketamine in Treatment-Resistant Major Depressive Disorder

Egypt70 participantsStarted 2025-07-01

Plain-language summary

This study aimed to compare the efficacy, safety, and tolerability of electroconvulsive therapy (ECT) versus intravenous (IV) ketamine in adults with treatment-resistant major depressive disorder (TRD).

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adults aged 18-75 years. * Current diagnosis of major depressive disorder (MDD) according to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria. * Treatment resistance defined as failure to respond to ≥2 adequate antidepressant trials in the current episode. * Montgomery-Åsberg Depression Rating Scale (MADRS) score ≥20. * Capacity to provide informed consent. Exclusion Criteria: * History of psychotic disorders or bipolar disorder. * Current substance use disorder. * Significant neurological disorders or traumatic brain injury. * Uncontrolled hyper- tension. * cardiovascular diseases in the past six months. * Pregnancy or breastfeeding.

What they're measuring

Change in Montgomery-Åsberg Depression Rating Scale

Timeframe: 3 weeks post-procedure

Trial details

NCT IDNCT07526454

SponsorTanta University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-02-01

View on ClinicalTrials.gov More Electroconvulsive Therapy trials